Telix (ASX:TLX) share price charges higher on FDA update

The Telix Pharmaceuticals Ltd (ASX:TLX) share price is charging higher on Thursday after releasing an update on its FDA submission for TLX591-CDx…
The post Telix (ASX:TLX) share price charges higher on FDA update appeared first on Motley Fool Australia. –

Biotechnology graphics

The market may be dropping lower today but that hasn’t stopped the Telix Pharmaceuticals Ltd (ASX: TLX) share price from charging higher.

In morning trade the biopharmaceutical company’s shares are up 3.5% to $1.82.

Why is the Telix share price charging higher?

Investors have been buying Telix’s shares on Thursday after it provided an update on its TLX591-CDx product.

TLX591-CDx is a proprietary formulation of PSMA-11, a novel imaging agent targeting prostate-specific membrane antigen (PSMA). It was originally developed by the Heidelberg group of the Deutsches Krebsforschungszentrum.

The cold kit format of TLX591-CDx enables rapid radiolabelling at room temperature with high radiochemical purity and production consistency, optimised for the radiopharmacy setting.

What was today’s update?

This morning Telix revealed that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for TLX591-CDx.

This NDA submission includes clinical data from over 600 patients obtained from both prospective and retrospective clinical studies. It also builds on definitive peer-reviewed clinical research conducted at leading academic centres. These include the University of California, the Peter MacCallum Cancer Centre in Australia, and the Heidelberg University Hospital in Germany.

A significant milestone.

Telix USA President, Dr Bernard Lambert, commented: “We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States.”

“Telix has engaged with the FDA since July 2019, with valuable guidance resulting in what we believe to be a comprehensive submission. Subject to FDA approval, we look forward to bringing this product to market with our commercial partners to serve the needs of men living with prostate cancer,” he added.

Telix’s CEO, Dr Christian Behrenbruch, believes this submission is a “major commercial inflection point” for the company.

“The Telix team and our advisors have done an outstanding job of preparing this submission, which we believe is founded on compelling clinical evidence that supports broad diagnostic utility in the management of prostate cancer,” Dr Behrenbruch concluded.

No date has been given for when an FDA decision is likely to be announced.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Telix (ASX:TLX) share price charges higher on FDA update appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!